Skip to main content
. 2009 Sep 1;114(18):3793–3802. doi: 10.1182/blood-2009-03-208181

Figure 2.

Figure 2

CTLs fail to control advanced AML disease in vivo. B6 mice (10 mice/group) were injected with 106 C1498FFDsR cells through an intravenous route 14 days before being infused with 30 × 106 CTLs. Mice were then monitored for survival. Infusion of CTLs 14 days after tumor injection showed no reduction of AML burden (A, ■ vs ▴) or survival advantage (B, ■ vs ▴). Results from 1 of 5 representative experiments are shown.

HHS Vulnerability Disclosure